believers and non nelievers, page-5

Like many I have been following the recent discussion about PRR with interest.

I confess to a poor understanding of all the financial debate regarding the options, and remain a bit uncertain as to what I'll call the 'ethics' of the release, but I just can't accept what I see as an implied criticism of the company's very reason for existence.

That is, do the people running this company actually believe they have a product that will benefit those who suffer from a disease that currently has no overall effective treatment, and are they working hard to get this product to the point where it is being used by clinical oncologists?

If the negative posts about PRR are accepted on face value it seems one conclusion being reached is that the people behind this company are using the false hope of a treatment for Ovarian cancer as a means to get wealthy.

Forgive my possible naievity but I just cannot accept this view. If their position is correct then this is not about PRR potentially selling out shareholders - it is about them potentially selling out Ovarian cancer patients. I'm not going to suggest this cannot happen, as human nature is what it is, I'd just be shocked if it did in PRR's case.

If you think that the primary motivation of the Directors of this company (and Dr Ian Frazer)is to get rich, with a hopeful side benefit of helping patients, then sell your stock immediatly. If like me, though, you believe that they genuinely want to produce an effective treatment for Ovarian cancer, and help real patients with this disease live longer, with financial benefit a secondary concern, then stick with them.

I do accept that worthwhile medical products can fall by the wayside if management is poor or without ongoing financial backing (Ventracor for example), or they can fall at several regulatory hurdles along the way, but so far PRR is still moving forward.

For the sake of Ovarian cancer patients I'm willing to stick by management, and believe that their primary motivation is a scientific/medical one, and not finanical.

If the product turns out to be not as promising as hoped, then so be it. That is the Biostock risk.

But if it is then I'll be pleased with having made a few dollars, but I'll mostly be pleased that my next patient with Ovarian cancer will have a treatment option that may significantly help their survival chances.